The Enterprise Value as of September 2024 (TTM) for Immunome, Inc. (IMNM) is 782.70M

According to Immunome, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 782.70M. This represents a change of 361.80% compared to the average of 169.49M of the last 4 quarters.

Immunome, Inc. (IMNM) Historical Enterprise Value (quarterly & annually)

How has IMNM Enterprise Value performed in the past?

The mean historical Enterprise Value of Immunome, Inc. over the last ten years is 58.38M. The current 782.70M Enterprise Value has changed 133.98% with respect to the historical average. Over the past ten years (40 quarters), IMNM's Enterprise Value was at its highest in in the June 2024 quarter at 568.67M. The Enterprise Value was at its lowest in in the March 2024 quarter at -40168729.53.

Immunome, Inc. (IMNM) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Immunome, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Immunome, Inc. (IMNM) Average Enterprise Value

How has IMNM Enterprise Value performed in the past?

The current Enterprise Value of Immunome, Inc. (IMNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Immunome, Inc. (IMNM) Enterprise Value vs. Peers

How is IMNM’s Enterprise Value compared to its peers?

Immunome, Inc.’s Enterprise Value is greater than Anebulo Pharmaceuticals, Inc. (49.05M), greater than Adagene Inc. (50.40M), greater than Acrivon Therapeutics, Inc. Common Stock (221.48M), less than AnaptysBio, Inc. (1.48B), greater than Mineralys Therapeutics, Inc. (509.47M), greater than Molecular Partners AG (-9807180.92), greater than MediciNova, Inc. (45.91M), greater than Champions Oncology, Inc. (72.61M), greater than Cyteir Therapeutics, Inc. (-20511738.00), greater than Aerovate Therapeutics, Inc. (25.04M), greater than Rezolute, Inc. (282.08M), greater than AN2 Therapeutics, Inc. (4.27M), greater than Gain Therapeutics, Inc. (21.66M), greater than TFF Pharmaceuticals, Inc. (3.55M), greater than aTyr Pharma, Inc. (138.44M), greater than IN8bio, Inc. (10.13M), greater than Lantern Pharma Inc. (27.93M), greater than Ikena Oncology, Inc. (47.83M), greater than Celcuity Inc. (628.91M),

Build a custom stock screener for Immunome, Inc. (IMNM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immunome, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Immunome, Inc. (IMNM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Immunome, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.